TCR peptide vaccination induced TH2 immune regulation in multiple sclerosis

Arthur Vandenbark, Y. K. Chou, Ruth Whitham, A. Buenafe, D. Liefeid, D. Cavanagh, S. Cooper, G. A. Hashim, Halina Offner, Dennis Bourdette

Research output: Contribution to journalArticle

Abstract

Oligoclonal Thl responses to neuroantigens such as myelin basic protein (MBP) may contribute to the pathogenesis of MS, raising the possibility of TCR peptide vaccines to induce anti-idiotypic regulation. Twenty-three patients with progressive MS were treated for 12 months with native VB5.2 CDR2 peptide, a cross-reactive Y49T-substituted VB5.2 CDR2 peptide, or placebo, and evaluated in a double-blinded fashion for clinical and immunological changes. Patients had more frequent and stronger T cell response to the substituted versus native VB5.2 CDR2 peptide, and response to either peptide was significantly associated with clinical benefit and decreased T cell response to MBP. T cell clones recognizing the VB5.2 peptide were predominantly HLA-DR restricted Th2 cells that inhibited activation of Thl cells specific for MBP by releasing locally suppressive lymphokines, predominantly IL-10, that may affect both the initiating and bystander Thl specificities. These results suggest a therapeutic potential for altered peptides that cross-react with TCR sequences involved in recognition of autoantigens.

Original languageEnglish (US)
JournalFASEB Journal
Volume10
Issue number6
StatePublished - 1996

Fingerprint

sclerosis
Multiple Sclerosis
Vaccination
vaccination
peptides
Peptides
Myelin Basic Protein
T-cells
T-lymphocytes
T-Lymphocytes
autoantigens
lymphokines
Th2 Cells
Subunit Vaccines
Lymphokines
subunit vaccines
Autoantigens
HLA-DR Antigens
interleukin-10
Interleukin-10

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

TCR peptide vaccination induced TH2 immune regulation in multiple sclerosis. / Vandenbark, Arthur; Chou, Y. K.; Whitham, Ruth; Buenafe, A.; Liefeid, D.; Cavanagh, D.; Cooper, S.; Hashim, G. A.; Offner, Halina; Bourdette, Dennis.

In: FASEB Journal, Vol. 10, No. 6, 1996.

Research output: Contribution to journalArticle

Vandenbark, A, Chou, YK, Whitham, R, Buenafe, A, Liefeid, D, Cavanagh, D, Cooper, S, Hashim, GA, Offner, H & Bourdette, D 1996, 'TCR peptide vaccination induced TH2 immune regulation in multiple sclerosis', FASEB Journal, vol. 10, no. 6.
Vandenbark, Arthur ; Chou, Y. K. ; Whitham, Ruth ; Buenafe, A. ; Liefeid, D. ; Cavanagh, D. ; Cooper, S. ; Hashim, G. A. ; Offner, Halina ; Bourdette, Dennis. / TCR peptide vaccination induced TH2 immune regulation in multiple sclerosis. In: FASEB Journal. 1996 ; Vol. 10, No. 6.
@article{aee58ead675444cd8019d97b374c821a,
title = "TCR peptide vaccination induced TH2 immune regulation in multiple sclerosis",
abstract = "Oligoclonal Thl responses to neuroantigens such as myelin basic protein (MBP) may contribute to the pathogenesis of MS, raising the possibility of TCR peptide vaccines to induce anti-idiotypic regulation. Twenty-three patients with progressive MS were treated for 12 months with native VB5.2 CDR2 peptide, a cross-reactive Y49T-substituted VB5.2 CDR2 peptide, or placebo, and evaluated in a double-blinded fashion for clinical and immunological changes. Patients had more frequent and stronger T cell response to the substituted versus native VB5.2 CDR2 peptide, and response to either peptide was significantly associated with clinical benefit and decreased T cell response to MBP. T cell clones recognizing the VB5.2 peptide were predominantly HLA-DR restricted Th2 cells that inhibited activation of Thl cells specific for MBP by releasing locally suppressive lymphokines, predominantly IL-10, that may affect both the initiating and bystander Thl specificities. These results suggest a therapeutic potential for altered peptides that cross-react with TCR sequences involved in recognition of autoantigens.",
author = "Arthur Vandenbark and Chou, {Y. K.} and Ruth Whitham and A. Buenafe and D. Liefeid and D. Cavanagh and S. Cooper and Hashim, {G. A.} and Halina Offner and Dennis Bourdette",
year = "1996",
language = "English (US)",
volume = "10",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "6",

}

TY - JOUR

T1 - TCR peptide vaccination induced TH2 immune regulation in multiple sclerosis

AU - Vandenbark, Arthur

AU - Chou, Y. K.

AU - Whitham, Ruth

AU - Buenafe, A.

AU - Liefeid, D.

AU - Cavanagh, D.

AU - Cooper, S.

AU - Hashim, G. A.

AU - Offner, Halina

AU - Bourdette, Dennis

PY - 1996

Y1 - 1996

N2 - Oligoclonal Thl responses to neuroantigens such as myelin basic protein (MBP) may contribute to the pathogenesis of MS, raising the possibility of TCR peptide vaccines to induce anti-idiotypic regulation. Twenty-three patients with progressive MS were treated for 12 months with native VB5.2 CDR2 peptide, a cross-reactive Y49T-substituted VB5.2 CDR2 peptide, or placebo, and evaluated in a double-blinded fashion for clinical and immunological changes. Patients had more frequent and stronger T cell response to the substituted versus native VB5.2 CDR2 peptide, and response to either peptide was significantly associated with clinical benefit and decreased T cell response to MBP. T cell clones recognizing the VB5.2 peptide were predominantly HLA-DR restricted Th2 cells that inhibited activation of Thl cells specific for MBP by releasing locally suppressive lymphokines, predominantly IL-10, that may affect both the initiating and bystander Thl specificities. These results suggest a therapeutic potential for altered peptides that cross-react with TCR sequences involved in recognition of autoantigens.

AB - Oligoclonal Thl responses to neuroantigens such as myelin basic protein (MBP) may contribute to the pathogenesis of MS, raising the possibility of TCR peptide vaccines to induce anti-idiotypic regulation. Twenty-three patients with progressive MS were treated for 12 months with native VB5.2 CDR2 peptide, a cross-reactive Y49T-substituted VB5.2 CDR2 peptide, or placebo, and evaluated in a double-blinded fashion for clinical and immunological changes. Patients had more frequent and stronger T cell response to the substituted versus native VB5.2 CDR2 peptide, and response to either peptide was significantly associated with clinical benefit and decreased T cell response to MBP. T cell clones recognizing the VB5.2 peptide were predominantly HLA-DR restricted Th2 cells that inhibited activation of Thl cells specific for MBP by releasing locally suppressive lymphokines, predominantly IL-10, that may affect both the initiating and bystander Thl specificities. These results suggest a therapeutic potential for altered peptides that cross-react with TCR sequences involved in recognition of autoantigens.

UR - http://www.scopus.com/inward/record.url?scp=33748883777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748883777&partnerID=8YFLogxK

M3 - Article

VL - 10

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 6

ER -